Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

2 recruiting

Phase 1

3(60.0%)

Phase 2

2(40.0%)

5Total

Phase 1(3)

Phase 2(2)

Loading network data...

Showing 5 of 5 trials

A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy

Role: lead

A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Role: lead

A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor

Role: lead

A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas

Role: lead

Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors

Role: lead

All 5 trials loaded